Tech Stock Valuations

Major technology and healthcare stocks are flashing warning signals as valuations reach stretched levels, with market technicians flagging overbought conditions across a narrow group of names that have surged despite broader uncertainty about artificial intelligence profitability and macroeconomic headwinds.

Alphabet Enters Overbought Territory on AI Optimism

Alphabet has emerged as one of the most technically extended stocks in the S&P 500 following a sharp rally driven by investor enthusiasm around its Gemini 3 artificial intelligence model and custom chip technology. The company’s 14-day relative strength index, or RSI, hit 72.2 this week—a level typically associated with overbought conditions that can precede near-term pullbacks in equity prices.

The buying interest reflects a shift in market sentiment regarding which companies may ultimately prevail in the race to commercialize advanced AI systems. Following disappointment surrounding OpenAI’s recent funding announcements and the modest reception to ChatGPT-5’s August release, investors redirected capital toward established technology firms with proven infrastructure and revenue streams.

Some investors are petrified that Alphabet will win the AI war due to huge improvements in its Gemini AI model and ongoing benefits from its custom TPU chip.

— Ben Reitzes, Melius Research

Alphabet’s proprietary Tensor Processing Units and the rollout of Gemini 3 features within its search engine represent tangible technological advantages that analysts believe could strengthen the company’s dominant market position. The integration of these AI capabilities into the core search business addresses investor concerns about whether massive capital expenditures will eventually translate into sustainable competitive advantages.

Over the past twelve months, Alphabet shares have climbed substantially as capital rotated into select artificial intelligence beneficiaries. This week’s additional gains, however, have pushed the stock into technically extended territory where historical patterns suggest limited near-term upside potential.

Within the broader artificial intelligence industry landscape, Alphabet commands approximately 92 percent of the global search market, providing an unparalleled distribution channel for AI-enhanced products and services. This structural advantage distinguishes the company from pure-play AI infrastructure vendors and positions it to capture disproportionate value from the transition toward intelligent systems. The market’s recognition of this moat has contributed substantially to the stock’s recent outperformance relative to peers with comparable AI capabilities but weaker incumbent business franchises.

Broader Market Rotation Away from Technology

The narrowing group of overbought stocks contrasts sharply with broader market performance in November, when major indices struggled with headwinds from elevated valuations and lingering questions about when artificial intelligence investments will generate measurable profits.

The Nasdaq Composite declined 1.5 percent during November, snapping a seven-month winning streak that had driven technology stocks substantially higher. The S&P 500 and Dow Jones Industrial Average barely managed small gains for the month as investors reassessed whether current price levels fairly reflect long-term growth prospects across the sector.

This concentration raises questions about market breadth and the sustainability of gains among stocks that have already experienced significant advances. Technical analysts monitor such conditions as potential warning signs that reversals may be imminent, particularly when broader market momentum shows signs of deterioration.

The disparity between narrowly concentrated strength in mega-cap technology names and weakness across the remainder of the market reflects a fundamental tension in investor positioning. Capital allocation toward artificial intelligence infrastructure and related technologies has intensified competitive pressures across the industry, creating winners and losers that the broader market has struggled to differentiate. Companies lacking clear pathways to monetize AI investments face deteriorating valuation multiples, while those perceived as AI leaders command premium pricing despite execution risks that remain unproven.

Healthcare and Consumer Names Join the Overbought List

Beyond technology, pharmaceutical and retail stocks have also reached overbought conditions, signaling that stretched valuations have spread beyond just artificial intelligence-related equities. Merck pharmaceutical posted a 14-day RSI of 80—the highest reading among the group—following strong quarterly earnings and several strategic announcements.

The drugmaker reported third-quarter results that exceeded consensus expectations, driven by robust demand for its cancer immunotherapy treatment, Keytruda. Merck subsequently narrowed its full-year profit forecast after revising tariff cost estimates and adjusting for various other items, yet the market responded positively to the overall earnings narrative.

In mid-November, Merck announced plans to acquire Cidara Therapeutics for approximately $9.2 billion, securing access to an experimental influenza therapeutic. The acquisition represents management’s confidence in the company’s pipeline and its ability to generate returns from early-stage drug candidates—a narrative that helped propel shares higher.

After the rally, Merck shares climbed more than 21% in November, with consensus analyst price targets implying only modest downside from current levels.

— LSEG Market Data

Despite the substantial monthly gain, analyst consensus price targets centered around $102.43 suggest limited additional upside, with implied downside of approximately 2 percent based on current market pricing. This disconnect between recent momentum and forward return expectations is precisely the pattern that technical overbought signals are designed to highlight.

The pharmaceutical industry broadly faces structural headwinds from patent cliffs, increased regulatory scrutiny around drug pricing, and competition from biosimilar manufacturers. Merck’s premium valuation reflects investor confidence in its pipeline depth and commercial execution capabilities, yet these advantages alone may not justify valuations that already price in successful commercialization of multiple late-stage candidates. The company’s $9.2 billion commitment to the Cidara acquisition signals aggressive portfolio diversification but introduces execution risks that markets have not fully discounted.

Valuation Concerns Amid AI Spending Questions

Underlying the overbought technical readings lies a more fundamental investor debate: whether massive artificial intelligence capital expenditures will eventually justify current equity valuations and generate sustainable returns. This uncertainty has created pressure across major technology stocks despite the significant advances that selected names have achieved.

The concentration of gains among a small number of overbought stocks, juxtaposed against weakness elsewhere in the market, suggests that broader investor appetite for risk has cooled considerably. Traders appear increasingly selective, rotating capital only toward companies with the most compelling near-term catalysts rather than embracing technology broadly.

Industry forecasters estimate that artificial intelligence infrastructure spending will reach $250 billion annually by 2028, concentrated among a handful of hyperscale cloud providers and semiconductor manufacturers. This concentration mirrors the current market pattern, where capital flows disproportionately toward companies perceived as industry leaders. However, the capital intensity of AI infrastructure deployment creates substantial risks for investors betting on continued multiple expansion. If artificial intelligence monetization disappoints relative to escalating infrastructure investments, the companies commanding premium valuations today face meaningful downside scenarios.

For investors monitoring these dynamics, the overbought readings serve as a technical reminder that recent rallies may lack the foundation necessary for sustained further advances. While fundamental improvements in artificial intelligence capabilities are real, the gap between technological progress and profitable business models remains substantial—a reality reflected in the hesitancy of broader market participation.

The technical signals emerging from this week’s screening suggest that risk-reward calculations have shifted meaningfully in favor of taking profits on recent winners rather than chasing further gains. Market participants should remain attentive to whether overbought conditions resolve through consolidation or outright pullbacks in the coming weeks. The persistence of overbought readings across technology and healthcare sectors, combined with deteriorating breadth metrics, creates an environment where tactical pullbacks should be anticipated regardless of longer-term secular trends supporting artificial intelligence adoption.